Year 2013

WIPO Seminar Discusses Impact Of TRIPS On Pharmaceutical Innovation

The latest instalment of the World Intellectual Property Organization seminar series titled “The Economics of Intellectual Property” covered the issue of product patents in the pharmaceutical industry. Discussion focussed on the economics of intellectual property rights and how pharmaceutical patent protection might not be the sole culprit in the access to innovation problem.

Good Intentions Echo In Marrakesh At Start Of Negotiations On Treaty For The Blind

The World Intellectual Property Organization diplomatic conference expected to yield a treaty creating exceptions and limitations to copyright for the benefit of visually impaired people opened today in Marrakesh, Morocco.

Assurances of good faith and willingness to find solutions for remaining issues were given by delegates, while WIPO Director General Francis Gurry called for unity, King Mohammed VI talked about moral obligation in a royal message, and visually impaired people called for negotiators to create history. All nonetheless agreed on the importance of the copyright system.

US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market

The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs' entry into the market may not be immune from antitrust scrutiny but are not "presumptively" unlawful. The case was sent back to lower court.

US Supreme Court Restricts Gene Patents … A Little

Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.

EU Commissioner: PRISM Will Hurt US Businesses, Create EU Opportunities

European Commission Vice-President responsible for the Digital Agenda, Neelie Kroes, today told a US business group that revelations about the United States government's mass surveillance programmes would hurt US businesses, but create opportunities for European business. She also said the US should have been more transparent with the European Union and allow US companies to be more transparent, and risks undermining trust in digital services.